Results beat Finncap forecasts, 44p target price7 Jun 2022 14:48
Worth noting that these results beat Finncap's forecasts for adjusted EBITDA and PBT, and the £15.7m cash pile was also ahead of forecasts.
Finncap retain their 44p target rpice.
They summarise:
"The year-end order backlog increased 11% to a record £46.0m, which stood at £64.25m (+40%) on 31 May 2022, due to five contract wins in 2022, the most recent of which was a landmark £14.7m contract from an existing top five pharma company. This provides us with the confidence that the company should deliver on FY 2022 forecasts, but it shows that hVIVO is a trusted partner for global players seeking to leverage the increased adoption of challenge models. Management is focusing on driving utilisation rates at its facilities, helped by its expanded recruitment programme, which enables it now to provide volunteers for Phase 2 and 3 field trials.
We reiterate our 44p target price, based on a sum of the parts valuation. Of this, the core business is valued at 33p (4.4x 2022 EV/Sales), which reflects the strong revenue growth (+33%) and arguably the company’s unique expertise and strategic positioning."
"- Forecasts. We are leaving forecasts unchanged for the time being, which implies revenue growth of 33% and adjusted EBITDA growth of 149% with margins expected to rise 670bps to 14.3% and on track towards the 20% target. We forecast year-end cash of £17.1m and net debt of £16.8m.
- Valuation. Despite the pull-back in the broader market, we leave our target price of 44p unchanged. This is based on a sum of the parts valuation, with the core business valued at 33p (based on 4.4x 2022 EV/Sales), c.9p for its non-core assets and 2p of cash."